Jun 22, 2020
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
Jun 16, 2020
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
Jun 08, 2020
Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th
May 29, 2020
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
May 29, 2020
Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint(TM)
May 14, 2020
Prognostic Model Reveals High-risk Melanoma Patients that need a Clinical Trial
May 05, 2020
DelMar Pharmaceuticals [Nasdaq:DMPI] Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
Apr 02, 2020
Texas Right to Know Calls on US to Consider COVID-19 Ozone Therapy After It Shows Promise in Italy
Mar 04, 2020
DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors
Feb 13, 2020
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Jan 15, 2020
National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera(TM) MRD Testing in Stage II-III Colorectal Cancer
Dec 18, 2019
Quantum Leap Healthcare Collaborative Announces the Selection of Regeneron's Libtayo® (cemiplimab) and REGN3767 for Injection in the I-SPY 2 TRIAL for Breast Cancer
Dec 12, 2019
New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer
Dec 12, 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
Nov 25, 2019
DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM
Nov 21, 2019
Cancer Drugs and New Therapies for Dangerous Brain Tumors Advancinghl2Financialnewsmedia.com News Commentary
Sep 30, 2019
New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Aug 19, 2019
Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival, According to New Research in JNCCN
Jul 31, 2019
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
Jul 24, 2019
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme